Cantor starts Organogenesis at overweight, cites differentiated portfolio (NASDAQ:ORGO)
Bet_Noire Cantor Fitzgerald has initiated coverage of Organogenesis (NASDAQ:ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio. Cantor said it holds a favorable view…